COMMUNIQUÉS West-GlobeNewswire

Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017

15/02/2018 - 22:05

TUCSON, Ariz., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for [...]

Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome

15/02/2018 - 22:05

CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]

Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

15/02/2018 - 22:05

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron [...]

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call

15/02/2018 - 22:05

MENLO PARK, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT ) today announced it will report its 2017 financial results and provide a corporate update on February 22, 2018. The [...]

Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results

15/02/2018 - 22:05

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is [...]

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares

15/02/2018 - 22:02

Heidelberg, Germany, February 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the closing [...]

Allscripts announces fourth quarter and 2017 full-year results

15/02/2018 - 22:01

Fourth quarter GAAP revenue $517 million, $547 million non-GAAP, representing growth of 22 and 27 percent, respectively, year-over-year Fourth quarter GAAP EPS of $0.03; non-GAAP EPS of $0.18, up 29% Y/Y, the highest [...]

Allscripts to sell OneContent business to Hyland

15/02/2018 - 22:01

CHICAGO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX ) has signed a definitive agreement to sell its OneContent business to Hyland Software, Inc., a leading provider of content services solutions to the [...]

Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results

15/02/2018 - 22:00

Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration [...]

Burgess Source Achieves HITRUST CSF® Certification to Further Mitigate Risk in Third Party Privacy, Security and Compliance

15/02/2018 - 21:00

ALEXANDRIA, Va., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Burgess, an innovator in healthcare payment operations for over 20 years, today announced that Burgess Group's Source Application has earned Certified status for [...]

Inovalon to Participate at 2018 RBC Capital Markets Global Healthcare Conference

15/02/2018 - 19:00

BOWIE, Md., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV ), a leading technology company providing advanced, cloud-based platforms empowering a data-driven transformation from volume-based to value-based [...]

LHC Group Announces Fourth Quarter and Year-End 2017 Earnings Release and Conference Call Dates

15/02/2018 - 18:00

LAFAYETTE, La., Feb. 15, 2018 (GLOBE NEWSWIRE) -- LHC Group, Inc . (NASDAQ: LHCG ) today announced details for the release of its results for the fourth quarter and year ended December 31, 2017. LHC Group plans to issue [...]

FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation

15/02/2018 - 17:58

– PDUFA date set for August 21, 2018 – CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic [...]

Diaxonhit : Distribution exclusive de la plateforme de biologie moléculaire VERIGENE®

15/02/2018 - 17:54

Distribution exclusive de la plateforme de biologie moléculaire VERIGENE® Diaxonhit devient, par l'intermédiaire de sa filiale eurobio-ingen, le distributeur exclusif de la gamme de biologie moléculaire VERIGENE® de la [...]

GUERBET : 2017 revenue at constant exchange rates: €812.4 million; +4.7%

15/02/2018 - 17:47

Villepinte, February 15, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €807.1 million at December 31, 2017, up by 4.0% at current [...]

GUERBET : Chiffre d'affaires 2017 à taux de change constant : 812,4 M€ ; +4,7%

15/02/2018 - 17:47

Villepinte, le 15 février 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un chiffre d'affaires de 807,1 M€ au 31 décembre 2017, en [...]

Catalyst Biosciences Announces Closing of Public Offering of Common Stock

15/02/2018 - 17:43

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]

PetVivo Holdings, Inc. Adds Special Revenue Consultant Approaching Commercial Production

15/02/2018 - 17:22

MINNEAPOLIS, Feb. 15, 2018 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. ( www.petvivo.com ) (OTCMARKET:PETV) an emerging biomedical device Company, is moving Mr. David Merrill, a member of the Board of Directors, to cover [...]

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer

15/02/2018 - 17:15

SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage [...]